The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; The results of multicenter, prospective Polish adult leukemia group study

• Published in: American journal of hematology Vol. 86; no. 5; pp. 437 - 439
• Main Authors: Grosicki, Sebastian, Holowiecki, Jerzy, Giebel, Sebastian, Kyrcz‐Krzemien, Slawomira, Kuliczkowski, Kazimierz, Kielbinski, Marek, Skotnicki, Aleksander B., Piatkowska‐Jakubas, Beata, Hellmann, Andrzej, Wierzbowska, Agnieszka, Stella‐Holowiecka, Beata, Zdziarska, Barbara, Calbecka, Malgorzata
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.05.2011; Wiley-Liss; Wiley Subscription Services, Inc
• Subjects: Adolescent; Adult; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Biomarkers; Bone Marrow Cells - drug effects; Bone Marrow Cells - pathology; Cell Count; Cohort Studies; Hematologic and hematopoietic diseases; Hematology; Hematopoietic Stem Cells - drug effects; Humans; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - drug therapy; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Middle Aged; Poland; Prognosis; Remission Induction; Survival Analysis; Time Factors; Young Adult; Poland; Europe; Human; Acute myelogenous leukemia; Hematology; Multicenter study; Malignant hemopathy; Blast; Survival; Induction treatment; Prospective; Bone marrow; Adult; Early; Remission; Cancer
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/ajh.21996

The aim of this study was to prospectively evaluate the impact of early bone marrow response on complete remission (CR) rate and long-term outcome in adults with acute myeloid leukemia. Bone marrow cytology was assessed on day 6 of induction treatment in 164 patients, revealing the presence of ≥5% blasts in 61 cases. In this subgroup the CR rate was significantly lower compared to the remaining patients (P < 0.00001) resulting in decrease of the overall survival (P = 0.002). Persistence of ≥5% blasts in bone marrow on day 6 of induction is an easily available surrogate marker to be used for treatment decisions.